A new analyst report from Stifel Financial Corp. is published.

'Pharming has announced the completion of enrolment into its international 30-patient Phase II prophylaxis trial of Ruconest for the treatment of hereditary angioedema (HAE). Results of the trial are expected at the end of 2Q16. Partnered with Valeant, Ruconest has had a successful roll-out in the US since its launch there in November 2014 as an acute treatment for HAE. We forecast sales of Ruconest of $335m in 2020E of which we forecast $85m from prophylactic use. We continue to believe the successful roll-out of Ruconest in the US and the potential for the product are not adequately reflected in Pharming's share price and reiterate our Buy rating and €0.88 target price.'

Visit our Analyst Coverage & Reports page to read more reports from Stifel Financial Corp.

Contact

Sijmen de Vries, CEO: T: +31 (0)71 524 7400

'This update is for informational purposes only and is not viewed by Pharming to be of a price sensitive nature'

Pharming Group NV issued this content on 2016-01-06 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 2016-01-07 20:35:04 UTC

Original Document: http://www.pharming.com/archives/2566